Orthoebolavirus

Orthoebolavirus (formerly designated Ebolavirus prior to the 2023 International Committee on Taxonomy of Viruses [ICTV] binomial nomenclature revision) is a genus of filamentous, enveloped, non-segmented negative-sense single-stranded RNA viruses within the family Filoviridae and order Mononegavirales. First identified in 1976 during concurrent central African outbreaks in Yambuku, Zaire (now the Democratic Republic of the Congo, DRC), and Nzara, Sudan, the genus comprises six distinct ICTV-recognized species: Orthoebolavirus zairense (Ebola virus, EBOV), Orthoebolavirus sudanense (Sudan virus, SUDV), Orthoebolavirus bundibugyoense (Bundibugyo ebolavirus, BDBV), Orthoebolavirus taiense (Taï Forest virus, TAFV), Orthoebolavirus restonense (Reston virus, RESTV), and Orthoebolavirus bombaliense (Bombali virus, BOMV).

Although the six Orthoebolavirus species share an identical seven-gene genomic layout (3′-NP-VP35-VP40-GP-VP30-VP24-L-5′), co-transcriptional RNA editing of the GP gene, and obligate dependence on the host endosomal receptor Niemann–Pick C1 (NPC1), their genomes diverge by 30% to 42% at the nucleotide level and by 35% to 45% in amino-acid sequence across the surface viral envelope glycoprotein (GP_1,2). Consequently, the six species differ markedly in primate pathogenicity, geographic reservoir distribution, and antigenic cross-reactivity—a critical public-health reality underscored when monovalent vaccines and monoclonal antibody therapy stockpiles engineered solely for Orthoebolavirus zairense (EBOV) cannot cross-neutralize divergent species such as Bundibugyo ebolavirus or Sudan virus.

Phylogenomic reconstruction across full-length ~18.9 kb genomes places the five African Orthoebolavirus species into three main evolutionary clades that diverged from a common ancestor several thousand years ago, with Asian Orthoebolavirus restonense branching near Sudan virus and Bombali virus occupying a basal sister position:

Species-Specific Pathogenicity Determinants (EBOV vs. RESTV and BOMV)

A central question in comparative virology is why Orthoebolavirus zairense (EBOV), Sudan virus (SUDV), and Bundibugyo ebolavirus (BDBV) cause severe systemic disease in humans, whereas Orthoebolavirus restonense (RESTV)—which causes high-mortality Epizootic Hemorrhagic Fever in cynomolgus macaques (Macaca fascicularis) and circulates in domestic pigs and Miniopterus bats in the Philippines—produces only asymptomatic seroconversion in exposed human animal handlers. Comparative reverse-genetics and structural studies point to three multi-genic differences:

1. Differential STAT1 Antagonism by VP24: While RESTV VP24 still binds human karyopherin-α nuclear import adaptors, hydrogen-deuterium exchange mass spectrometry shows that RESTV VP24 binds with lower stability than EBOV VP24, permitting residual nuclear translocation of phosphorylated STAT1 and partial preservation of human interferon-stimulated gene expression.
2. Cleavage Efficiency and NPC1 Affinity of GP: In Orthoebolavirus bombaliense (BOMV), isolated from free-tailed insectivorous bats (Mops condylurus and Chaerephon pumilus) in Sierra Leone, Kenya, and Mozambique, natural amino-acid substitutions at the Niemann–Pick C1 (NPC1) Domain C binding interface reduce fusion efficiency in human cells compared to bat cells.
3. TLR4 Activation by Shed Glycoprotein: Metalloprotease (TACE/ADAM17) shedding of surface EBOV GP_1,2 releases soluble trimeric shed GP, which activates Toll-like receptor 4 (TLR4) on human monocytes and macrophages to trigger pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β) and vascular endothelial barrier permeability; RESTV shed GP triggers markedly lower TLR4 signaling in human primary macrophages.

The Heptauridine Editing Switch and Antigenic Subversion

Unlike Orthomarburgvirus, every species in the genus Orthoebolavirus splits its fourth gene (GP) across two overlapping reading frames connected by a seven-uridine slippery sequence (3′-UUUUUUU-5′). Unedited mRNA transcripts (~70–80%) encode the 364-amino-acid precursor of secreted glycoprotein (sGP), which is cleaved by furin into mature homodimeric sGP (linked by two antiparallel disulfide bonds between Cys53 and Cys306) and a small heavily O-glycosylated peptide termed Δ-peptide (viroporin candidate).

Because sGP shares its entire N-terminal 295-amino-acid sequence with the surface receptor-binding subunit GP₁ but folds as a parallel homodimer rather than a chalice-shaped homotrimer, high concentrations of circulating sGP in patient plasma perform antigenic subversion: they redirect the host germinal-center B-cell response toward non-neutralizing epitopes shared between sGP and the outer glycan cap of GP₁, while absorbing cross-reactive antibodies before they can reach infectious virions.

Structural Basis of Species-Specific Neutralization vs. Pan-Genus Epitopes

When X-ray and cryo-EM structures of the trimeric viral envelope glycoprotein (GP_1,2) are compared across EBOV, SUDV, and Bundibugyo ebolavirus, amino-acid conservation varies sharply from the top of the trimer chalice to its membrane-proximal stalk:

• Hypervariable Mucin-Like Domain (MLD) and Glycan Cap (<30–55% identity): Projecting upward and outward from the three GP₁ protomers, the MLD and glycan cap shield the recessed NPC1 receptor-binding pocket prior to endosomal cathepsin cleavage. Because these solvent-exposed surfaces tolerate extensive sequence variation without impairing receptor binding, neutralizing antibodies that bind solely to the glycan cap or MLD-cradle of Zaire ebolavirus fail to bind BDBV or SUDV.
• Conserved Receptor-Binding Core, Internal Fusion Loop, and Stalk (>80–90% identity): Beneath the glycan cap, the 19-kDa GP₁ receptor-binding crest (which must match invariant human NPC1 Domain C) and the GP₂ internal fusion loop (IFL) and HR1/HR2 stalk (which execute six-helix-bundle membrane fusion) are tightly constrained by purifying selection. Second-generation pan-Orthoebolavirus monoclonal antibody therapy combinations such as MBP134 (combining ADI-15878, which locks the conserved internal fusion loop across all known species, with ADI-23774, which targets the base/stalk) exploit these conserved structural bottlenecks to neutralize EBOV, SUDV, and BDBV simultaneously.

Zoonotic Spillover Corridors and Rural-to-Urban Transmission Chains

Historically, human outbreaks of Orthoebolavirus began as localized zoonotic spillover events in equatorial rainforest villages of the Congo Basin (DRC, Republic of the Congo, Gabon), South Sudan, and Uganda—often linked to hunting or butchering infected forest wildlife (chimpanzees, Western lowland gorillas, forest duikers) or direct exposure to pteropodid fruit bat roosts. In isolated rural settings, transmission chains typically remained under several hundred cases before being extinguished through case isolation and contact tracing.

However, when spillover or secondary importation reaches dense road corridors, mining towns, and regional air/land transit hubs—as occurred during the 2014–2016 West African EBOV epidemic (>28,600 cases across Guinea, Liberia, and Sierra Leone), the 2018–2020 North Kivu/Ituri DRC epidemic (3,470 cases), and the multi-province Bundibugyo ebolavirus emergency across the DRC and regional transit corridors—human-to-human transmission scales along household caregiving, nosocomial clinic, and funeral networks.

Immune-Privileged Persistence and Relapse Resurgence

Whole-genome sequencing of recent DRC and Guinean outbreaks has also transformed classical assumptions that every new outbreak represents a fresh wildlife spillover. In a small subset of convalescent survivors, viable Orthoebolavirus RNA can persist for months to several years inside immune-privileged anatomical compartments—including the seminiferous tubules of the testes, the aqueous humor of the eye (causing uveitis), the central nervous system, and the placenta/breast milk—where tight blood–tissue barriers limit antibody and cytotoxic T-cell surveillance. Phylogenetic molecular-clock analyses of the 2021 Nzérékoré (Guinea) and 2021–2022 North Kivu (DRC) outbreaks demonstrated far fewer nucleotide substitutions than expected from continuous evolutionary clock rates in wildlife reservoirs (~1.2 × 10⁻³ substitutions per site per year), proving that several post-2016 outbreaks arose from reactivation of persistent latent infection in survivors from an earlier wave.

Why did the ICTV change the genus name from Ebolavirus to Orthoebolavirus in 2023?

To prevent confusion between the genus name (Ebolavirus), the species name (Zaire ebolavirus), and the individual virus name (Ebola virus, EBOV), the International Committee on Taxonomy of Viruses (ICTV) standardized all viral species across virology into a strict Linnaean binomial format (Genus + specific epithet). Under this 2023 nomenclature, the genus became Orthoebolavirus and the six species were renamed Orthoebolavirus zairense, Orthoebolavirus sudanense, Orthoebolavirus bundibugyoense, Orthoebolavirus taiense, Orthoebolavirus restonense, and Orthoebolavirus bombaliense, while the vernacular virus names and abbreviations (EBOV, SUDV, BDBV, TAFV, RESTV, BOMV) remained unchanged.

Why does the licensed Ervebo (rVSV-ZEBOV) vaccine protect against Zaire ebolavirus but not Bundibugyo or Sudan ebolavirus?

Ervebo (rVSV-ZEBOV) is a live-attenuated recombinant vesicular stomatitis virus engineered to replace its native rhabdovirus G surface protein with the viral envelope glycoprotein (GP_1,2) of the 1976/1995 Kikwit strain of Orthoebolavirus zairense (EBOV). Most of the neutralizing antibodies elicited by single-dose rVSV-ZEBOV vaccination recognize the outer glycan cap and chalice rim of EBOV GP. Because Bundibugyo ebolavirus and Sudan virus differ from EBOV by 35% to 45% across their GP amino-acid sequences (and even more steeply across the surface glycan cap), Zaire-specific vaccine antibodies fail to bind or neutralize BDBV or SUDV virions.

How can genomic sequencing distinguish a brand-new bat spillover from a survivor relapse outbreak?

When Orthoebolavirus circulates continuously in its natural wildlife reservoir, its RNA-dependent RNA polymerase accumulates mutations at a steady evolutionary rate of roughly 0.8 × 10⁻³ to 1.2 × 10⁻³ substitutions per site per year (~15 to 22 nucleotide changes per genome per year). If a new human outbreak in 2026 stems from a fresh wildlife spillover, its genome branches deeply on the phylogenetic tree with dozens of new mutations relative to an earlier 2019 human outbreak. Conversely, if the virus lay dormant in a human survivor's immune-privileged tissue with minimal replication, its sequence sits directly on the tip of the 2019 human transmission branch with only a handful of substitutions ("molecular clock deceleration").

1. Benda, R., & ICTV Filoviridae Study Group / Kuhn, J. H., Adachi, T., Adhikari, N. K. J., Arribas, J. R., Bah, I. E., Bausch, D. G., Bhadelia, N., Borchert, M., Brantsæter, A. B., Brett-Major, D. M., Burgess, T. H., Caluwaerts, S., Chertow, D. S., Chimeremma, N., Crozier, I., Declerck, H., ... Zaki, S. R. (2023). New binomial species names for filoviruses. Archives of Virology, 168, 216. https://doi.org/10.1007/s00705-023-05834-2
2. Towner, J. S., Sealy, T. K., Khristova, M. L., Albariño, C. G., Conlan, S., Reeder, S. A., Quan, P.-L., Lipkin, W. I., Downing, R., Tappero, J. W., Okware, S., Lutwama, J., Bakamutumaho, B., Kayiwa, J., Comer, J. A., Rollin, P. E., Ksiazek, T. G., & Nichol, S. T. (2008). Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLOS Pathogens, 4(11), e1000212. https://doi.org/10.1371/journal.ppat.1000212
3. Mulangu, S., Dodd, L. E., Davey, R. T., Jr., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., Ali, R., Coulibaly, S., Levine, A. C., Grais, R., Diaz, J., Lane, H. C., Muyembe-Tamfum, J.-J., & the PALM Writing Group. (2019). A randomized, controlled trial of Ebola virus disease therapeutics. New England Journal of Medicine, 381(24), 2293–2303. https://doi.org/10.1056/NEJMoa1910993
4. Keita, A. K., Koundouno, F. R., Faye, M., Düx, A., Hinzmann, J., Diallo, H., Ayouba, A., Le Marcis, F., Soropogui, B., Ifono, K., Diagne, M. M., Sow, M. S., Bore, J. A., Calvignac-Spencer, S., Vidal, N., Camara, J., Keita, M. B., Renevey, A., ... Delaporte, E. (2021). Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature, 597(7877), 539–543. https://doi.org/10.1038/s41586-021-03901-9